Date: 2011-05-04
Type of information: R&D agreement
Compound: in vivo siRNA delivery technology
Company: Cenix Biosciences (Germany) Janssen Pharmaceutica (J&J-USA)
Therapeutic area: CNS diseases
Type agreement: R&D
Licensing
Action mechanism:
Disease:
Details: Cenix BioScience and its new subsidiary, Cenix BioScience Belgium , have signed a Collaboration and Technology License Agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV, to improve the in vivo applicability of siRNA-based experimentation, focusing on the further co-development of DARETM, a proprietary Cenix siRNA delivery technology. The new agreement represents a significant intensification of the research collaboration between Cenix and Janssen ongoing over the past two years, to improve siRNA-based target validation methodologies in vivo for use with CNS indications.The collaboration will also continue making in-depth use of the full range of Cenix strengths in siRNA-based research, including both its well-established high-throughput, high-content RNAi platform for detailed analyses of subcellular delivery paths and its still-growing in vivo RNAi unit using rodent models for several disease areas. Some of the novel delivery solutions co-developed by the two partners are also expected to carry strong potential for enabling therapeutic applications of siRNAs, including future improvements to DARETM technology, which will continue to be owned and controlled by Cenix.
Financial terms:
Latest news:
